TBI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. TBI just jumped ~8.9% into nearby resistance (R1 ~5.49) with no proprietary buy signal and weakening profitability trends. With an impatient profile, chasing here offers poor reward/risk versus waiting for either a clean breakout above ~5.49–5.68 or a pullback toward ~5.17 support.
Trend/price action: Strong up day (post-market ~5.36) but price is now close to first resistance (R1 5.487) after the pop, which reduces immediate upside. Momentum: MACD histogram is above zero and expanding (bullish momentum building). RSI(6) ~63 is neutral-to-slightly warm (not overbought, but no clear oversold edge). Moving averages: Converging MAs suggests the stock may be transitioning from consolidation into a potential trend, but confirmation is needed. Key levels: Pivot 5.172 (near-term “line in the sand”). Resistance at 5.487 then 5.682; supports at 4.857 then 4.662. Intellectia Proprietary Trading Signals:
Technical momentum is improving (MACD positive and expanding) and the stock just showed strong upside impulse.
Revenue growth remains positive in the latest quarter (2025/Q3 revenue +12.79% YoY).
Analyst stance remains positive: BMO maintains Outperform (even after cutting the target).
Potential catalyst ahead: next earnings on 2026-02-18 after hours could re-rate the stock if margins/profitability inflect.
immediately after a sharp one-day spike.
implies elevated risk of sharp reversals.
Latest quarter: 2025/Q3. Growth: Revenue rose to $431.266M (+12.79% YoY), indicating demand/top-line resilience. Profitability: Net income fell to -$1.916M (-74.91% YoY) and EPS to -$0.06 (-76.92% YoY), showing worsening earnings power. Margins: Gross margin declined to 21.24% (-12.74% YoY), a key negative trend—revenue growth is not translating into profits. Overall: Top-line improving, but margin/earnings trends are moving the wrong direction, which limits how aggressively the stock should be bought after a spike.
Recent change: (2025-11-05) BMO Capital maintained Outperform but lowered price target to $6 from $8. Interpretation: Wall Street “pro” view is cautiously constructive on relative performance/inflection versus pressured staffing peers, but the target cut signals tempered upside expectations and sensitivity to the cycle. Pros cited: margin-driven beat and better-than-peers resilience. Cons implied: macro/end-market uncertainty and limited valuation headroom given the reduced target.
